News

Cosmo’s tablets deliver the goods
Enlarge image

Clinical trialsItaly

Cosmo’s tablets deliver the goods

14.09.2012 - Cosmo's new anti-diarrhoea formulation of rifamycin meets the Phase III trial primary endpoints.

Cosmo Pharmaceuticals S.p.A. from Lainate (Lombardy) announced on 12 September the top-line results of a Phase III clinical trial with rifamycin SV MMX. Its US licensee Santarus, Inc. from San Diego (US) conducted a multicentre, randomised, placebo-controlled study where patients with traveller’s diarrhoea were treated with 800 mg rifamycin SV MMX a day for three consecutive days. The scored primary endpoints were a reduction of the time to last unformed stool (TLUS, down from 68 hours in placebo-group to 46 hours in active drug-group) and the clinical cure (56,9% placebo, 81,4% active treatment).

Cosmo is now awaiting results of  a second Phase III study conducted by German Dr. Falk Pharma GmbH from Freiburg. Here the drug is tested against ciprofloxacin treatment. The results are expected in H2/2012. Milestone payments from Santarus will be due at regulatory acceptance as well as at the successful conclusion of a Phase III trial in another indication. Cosmo is also having an interest in sales royalties which amount to more than 20% – plus certain revenue milestones.

Rifamycin SV is a non-systemic antibiotic which has been used for years intravenously and intramuscularly. Combined with Cosmos’s MMX delivery technology, the antibiotic now passes the upper gastrointestinal tract without degradation for final release in the colon. The lipophilic and amphiphilic matrices disperse within a hydrophilic matrix and are coated with gastro-resistant polymers. Cosmo, Santarus and Swiss Ferring Pharmaceuticals S.A. are also working together on another MMX drug named Ultesa/Uceris. That drug offers potentially improved side-effect profiles compared with established systemic corticosteroids used to treat ulcerative colitis. However, signs were bleak when the approval of the drug in the Netherlands failed in August.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-03/cosmos-tablets-deliver-the-goods.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR52.38%
  • THERAMETRICS0.08 CHF14.29%
  • WILEX2.96 EUR1.37%

FLOP

  • MOLOGEN5.68 EUR-28.01%
  • MORPHOSYS54.71 EUR-22.45%
  • MEDIGENE11.65 EUR-13.70%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR232.6%

FLOP

  • CYTOS1.40 CHF-54.2%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 26.03.2015